Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 29Neoplasms 5Glioma 4Ovarian Neoplasms 3Neoplasm Metastasis 3Melanoma 3Glioblastoma 3Rhabdoid Tumor 2Neoplasms, Germ Cell and Embryonal 2Medulloblastoma 2Lymphoma 2Liposarcoma 2Fallopian Tube Neoplasms 2Diffuse Intrinsic Pontine Glioma 2Brain Neoplasms 2Astrocytoma 2Thymus Neoplasms 1Teratoma 1Solid Tumors Harboring a BRAF V600 Mutation 1Sarcoma, Synovial 1Sarcoma 1Recurrence 1Pyloric Stenosis, Hypertrophic 1Prostatic Neoplasms 1Pinealoma 1Osteitis Deformans 1Oligodendroglioma 1Non functioning pancreatic endocrine tumor 1Neurofibrosarcoma 1Neuroendocrine Tumors 1

Interventions

ribociclib 1Pharmacogenomic Variants 1Aromatase Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Estrogen Receptor and/or Progesterone Receptor Positive × ribociclib × Clear all
NCT03477396 2024-02-20

Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer

City of Hope Medical Center

Phase 2 Completed
2 enrolled 13 charts
Breast

Estrogen Receptor and/or Progesterone Receptor Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡